Skip Navigation

This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Viniker, D.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viniker, D.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 11, No. 7, pp. 1435-1437, 1996
© 1996 European Society of Human Reproduction and Embryology

research-article

Infertility: Late luteal phase dydrogesterone in combination with clomiphene or tamoxifen in the treatment of infertility associated with irregular and infrequent menstruation: enhancing patient compliance

D.A. Viniker

Department of Obstetrics and Gynaecology, Whipps Cross Hospital London E11, UK

This pilot study was undertaken to determine whether dydrogesterone administered in the late luteal phase might have a potential benefit for Infertility associated with irregular and infrequent menstruation. Between April 1994 and February 1995, 54 normo-prolactinaemic women received either tamoxifen, if there was evidence of polycystic ovaries and/or increased luteinizing hormone (LH) secretion, or clomiphene together with dydrogesterone 10 mg twice daily on days 21–26 of the menstrual cycle. A total of 23 women (42.6%) conceived (10.7% per cyde). In 192 non-conception cycles the average cyde length was 29.6 days; 182 cycles (94.8%) were 34 days or less. Patients found the rapid onset of regular menstruation to be encouraging and compliance was excellent Controlled studies are indicated to determine whether the addition of dydrogesterone to oral ovarian stimulation is beneficial.

Key words: clomiphene/compliance/dydrogesteronelinfertility/tarnoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.